Jodie Morrison

Jodie Morrison, Chief Executive Officer and a member of the Board of Directors of Q32 Bio, Inc., brings biopharmaceutical leadership experience from private start up through commercial public biotechnology and pharmaceutical companies. Jodie was previously Chief Executive Officer of Cadent Therapeutics until its sale to Novartis in 2020. Jodie also served as Venture Partner of Atlas Venture, interim Chief Executive Officer of Keryx Biopharmaceuticals, Inc. (executed the merger of equals with Akebia Therapeutics, Inc. in 2018), acting Chief Operating Officer of Syntimmune, Inc. (acquired by Alexion Pharmaceuticals, Inc.), and President and Chief Executive Officer of Tokai Pharmaceuticals, Inc., where she oversaw the company’s successful initial public offering (IPO) in 2014. Prior, Jodie held other senior positions with the company, including Chief Operating Officer and Head of Clinical Affairs and Program Operations. Earlier in her career, Jodie held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc. and Diacrin, Inc.

Jodie founded and currently runs The CEO Forum, which has supported CEOs through challenges including the COVID-19 pandemic, the SVB banking crisis, the Inflation Reduction Act and the recent evolution of the BIOSECURE Act. Jodie currently serves as a member of the Board of Directors of Rectify Pharmaceuticals, Inc. and was previously a board member of Akebia Therapeutics, Inc., Aileron Therapeutics, Inc., Keryx Biopharmaceutics, Inc., Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics) and Ribon Therapeutics, Inc (chair). Jodie also serves on the Board of Managers of Life Science Cares (LSC). Jodie holds a B.A. in Neuroscience from Mount Holyoke College, completed her business training in the Greater Boston Executive Program at the MIT Sloan School of Management and her clinical research certification from Boston University School of Medicine.